Results 1 to 6 of 6
Antipsychotic Drugs are Killing Patients
  1. #1
    Miles is offline Member
    Join Date
    Oct 2004
    Location
    USA.
    Posts
    330

    Default Antipsychotic Drugs are Killing Patients

    Brit Journal of Psychiatry
    Wednesday, 01 February 2006

    A major 17-year follow up study published in the British Journal of Psychiatry found a 2.84 times (95% CI 2.06–3.90) increased risk of mortality in people with schizophrenia compared to those not so diagnosed, and with each addition of a neuroleptic (antipsychotic) drug, the risk increased another 2.50.

    The Finnish study, published in the British Journal of Psychiatry, found even when adjusted for age and gender, the relative risk of natural death between people with schizophrenia and others was 2.80 (95% CI 2.00–3.93).

    "The risk of mortality was increased among people with schizophrenia even after controlling for potential risk factors for premature death (low level of education, smoking, alcohol intake, exercise, body mass index, systolic and diastolic pressure, and total and HDL cholesterol) and coexistent somatic diseases."

    The sample size was 8,000: the number of people with schizophrenia was 99--of whom 39 died in the course of the 17 year study.

    "Of the 99 people with schizophrenia, 20 were taking no neuroleptic drug at baseline, 31 one drug, 34 two drugs and 14 three or more drugs. The most commonly used neuroleptic was thioridazine (34%), followed by perphenazine (20%), chlorpromazine (19%), levomepromazine (14%), chlorprothixene (13%) and haloperidol (12%); use of other neuroleptics was less than 10%.

    Among participants with schizophrenia, there was a strong inverse relationship between serum HDL cholesterol and the number of neuroleptic drugs prescribed (correlation coefficient¼70.41, P50.001) that remained statistically significant after adjustment for age, gender, all lifestyle-related factors and coexistent somatic diseases."

    There were only four "unnatural deaths" (suicides ?) among those with schizophrenia.

    Of the 31 on one neuroleptic drug, 11 (35%) died; of the 34 on two drugs, 15 (44%) died; of the 14 on three or more neuroleptics, 8 (57%) died, compared to 5 (20%) who did not take a neuroleptic. The authors conclusion: "the association with neuroleptic drugs was very clear."

    They cited numerous studies with similar findings: a 10-year UK follow-up study; two French studies; two studies that tracked patients on the new atypical antipsychotics: one in the U.S., another in Sweden; two studies showing "large relative absolute increases in sudden cardiac deaths.

    Invited commentary by Dr. David Healy is disappointing in that he appears torn between loyalty to patients and scientific integrity, and loyalty to his professional colleagues who have so badly betrayed their patients by prescribing toxic neurologically damaging drugs that increase cardiovscular disease, cerebrovascular disease and respiratory disease. Neuroleptics (antipsychotics) are drugs that shorten life.

    Unlike Robert Whitaker, author of Mad in America and The Anatomy of an Epidemic (who is not a psychiatrist) Dr. Healy avoids rendering a judgement on psychiatry's dangerous obsession with drugs--which he tells us, Dr. Ross Baldessarini describes as "the allopathic compulsion." He averts his gaze from the mounting human casualties seeking comfort from Dr. Heinz Lehmann who introduced neuroleptics to the U.S. and Canada whose enthusiasm encapsulates what was and what still is wrong with psychiatry's obsession with the pill: Heinz transferred his and clinicians' enthusiasm with the pill onto patients: "I suppose if people had been told well they’ll die 2 years later they’d still have said it’s worth it. It was so unthinkable and so new and so wonderful’"

    Although Dr. Healy recognizes the folly "But yesterday’s enthusiasms commonly pall in the face of today’s hazards"--he rationalizes lethal clinical practice: "Understandably, though, in the face of non-response or minimal responses, right from the start some clinicians increased the dose of individual neuroleptics a hundred-fold beyond what is now recognised as optimal, or added further neuroleptics to treatment cocktails when a particular neuroleptic had failed... Sometimes these dose escalations or additional treatments have been given on the back of an apparently worsening clinical state that may in fact have been made somewhat worse by the treatment being administered."

  2. #2
    Omega2K is offline New Member
    Join Date
    Jun 2006
    Location
    , , USA.
    Posts
    2

    Default

    quote:Originally posted by Miles

    Brit Journal of Psychiatry
    Wednesday, 01 February 2006

    A major 17-year follow up study published in the British Journal of Psychiatry found a 2.84 times (95% CI 2.06–3.90) increased risk of mortality in people with schizophrenia compared to those not so diagnosed, and with each addition of a neuroleptic (antipsychotic) drug, the risk increased another 2.50.

    The Finnish study, published in the British Journal of Psychiatry, found even when adjusted for age and gender, the relative risk of natural death between people with schizophrenia and others was 2.80 (95% CI 2.00–3.93).

    "The risk of mortality was increased among people with schizophrenia even after controlling for potential risk factors for premature death (low level of education, smoking, alcohol intake, exercise, body mass index, systolic and diastolic pressure, and total and HDL cholesterol) and coexistent somatic diseases."

    The sample size was 8,000: the number of people with schizophrenia was 99--of whom 39 died in the course of the 17 year study.

    "Of the 99 people with schizophrenia, 20 were taking no neuroleptic drug at baseline, 31 one drug, 34 two drugs and 14 three or more drugs. The most commonly used neuroleptic was thioridazine (34%), followed by perphenazine (20%), chlorpromazine (19%), levomepromazine (14%), chlorprothixene (13%) and haloperidol (12%); use of other neuroleptics was less than 10%.

    Among participants with schizophrenia, there was a strong inverse relationship between serum HDL cholesterol and the number of neuroleptic drugs prescribed (correlation coefficient¼70.41, P50.001) that remained statistically significant after adjustment for age, gender, all lifestyle-related factors and coexistent somatic diseases."

    There were only four "unnatural deaths" (suicides ?) among those with schizophrenia.

    Of the 31 on one neuroleptic drug, 11 (35%) died; of the 34 on two drugs, 15 (44%) died; of the 14 on three or more neuroleptics, 8 (57%) died, compared to 5 (20%) who did not take a neuroleptic. The authors conclusion: "the association with neuroleptic drugs was very clear."

    They cited numerous studies with similar findings: a 10-year UK follow-up study; two French studies; two studies that tracked patients on the new atypical antipsychotics: one in the U.S., another in Sweden; two studies showing "large relative absolute increases in sudden cardiac deaths.

    Invited commentary by Dr. David Healy is disappointing in that he appears torn between loyalty to patients and scientific integrity, and loyalty to his professional colleagues who have so badly betrayed their patients by prescribing toxic neurologically damaging drugs that increase cardiovscular disease, cerebrovascular disease and respiratory disease. Neuroleptics (antipsychotics) are drugs that shorten life.

    Unlike Robert Whitaker, author of Mad in America and The Anatomy of an Epidemic (who is not a psychiatrist) Dr. Healy avoids rendering a judgement on psychiatry's dangerous obsession with drugs--which he tells us, Dr. Ross Baldessarini describes as "the allopathic compulsion." He averts his gaze from the mounting human casualties seeking comfort from Dr. Heinz Lehmann who introduced neuroleptics to the U.S. and Canada whose enthusiasm encapsulates what was and what still is wrong with psychiatry's obsession with the pill: Heinz transferred his and clinicians' enthusiasm with the pill onto patients: "I suppose if people had been told well they’ll die 2 years later they’d still have said it’s worth it. It was so unthinkable and so new and so wonderful’"

    Although Dr. Healy recognizes the folly "But yesterday’s enthusiasms commonly pall in the face of today’s hazards"--he rationalizes lethal clinical practice: "Understandably, though, in the face of non-response or minimal responses, right from the start some clinicians increased the dose of individual neuroleptics a hundred-fold beyond what is now recognised as optimal, or added further neuroleptics to treatment cocktails when a particular neuroleptic had failed... Sometimes these dose escalations or additional treatments have been given on the back of an apparently worsening clinical state that may in fact have been made somewhat worse by the treatment being administered."
    v

  3. #3
    Omega2K is offline New Member
    Join Date
    Jun 2006
    Location
    , , USA.
    Posts
    2

    Default

    quote:Originally posted by Miles

    Brit Journal of Psychiatry
    Wednesday, 01 February 2006

    A major 17-year follow up study published in the British Journal of Psychiatry found a 2.84 times (95% CI 2.06–3.90) increased risk of mortality in people with schizophrenia compared to those not so diagnosed, and with each addition of a neuroleptic (antipsychotic) drug, the risk increased another 2.50.

    The Finnish study, published in the British Journal of Psychiatry, found even when adjusted for age and gender, the relative risk of natural death between people with schizophrenia and others was 2.80 (95% CI 2.00–3.93).

    "The risk of mortality was increased among people with schizophrenia even after controlling for potential risk factors for premature death (low level of education, smoking, alcohol intake, exercise, body mass index, systolic and diastolic pressure, and total and HDL cholesterol) and coexistent somatic diseases."

    The sample size was 8,000: the number of people with schizophrenia was 99--of whom 39 died in the course of the 17 year study.

    "Of the 99 people with schizophrenia, 20 were taking no neuroleptic drug at baseline, 31 one drug, 34 two drugs and 14 three or more drugs. The most commonly used neuroleptic was thioridazine (34%), followed by perphenazine (20%), chlorpromazine (19%), levomepromazine (14%), chlorprothixene (13%) and haloperidol (12%); use of other neuroleptics was less than 10%.

    Among participants with schizophrenia, there was a strong inverse relationship between serum HDL cholesterol and the number of neuroleptic drugs prescribed (correlation coefficient¼70.41, P50.001) that remained statistically significant after adjustment for age, gender, all lifestyle-related factors and coexistent somatic diseases."

    There were only four "unnatural deaths" (suicides ?) among those with schizophrenia.

    Of the 31 on one neuroleptic drug, 11 (35%) died; of the 34 on two drugs, 15 (44%) died; of the 14 on three or more neuroleptics, 8 (57%) died, compared to 5 (20%) who did not take a neuroleptic. The authors conclusion: "the association with neuroleptic drugs was very clear."

    They cited numerous studies with similar findings: a 10-year UK follow-up study; two French studies; two studies that tracked patients on the new atypical antipsychotics: one in the U.S., another in Sweden; two studies showing "large relative absolute increases in sudden cardiac deaths.

    Invited commentary by Dr. David Healy is disappointing in that he appears torn between loyalty to patients and scientific integrity, and loyalty to his professional colleagues who have so badly betrayed their patients by prescribing toxic neurologically damaging drugs that increase cardiovscular disease, cerebrovascular disease and respiratory disease. Neuroleptics (antipsychotics) are drugs that shorten life.

    Unlike Robert Whitaker, author of Mad in America and The Anatomy of an Epidemic (who is not a psychiatrist) Dr. Healy avoids rendering a judgement on psychiatry's dangerous obsession with drugs--which he tells us, Dr. Ross Baldessarini describes as "the allopathic compulsion." He averts his gaze from the mounting human casualties seeking comfort from Dr. Heinz Lehmann who introduced neuroleptics to the U.S. and Canada whose enthusiasm encapsulates what was and what still is wrong with psychiatry's obsession with the pill: Heinz transferred his and clinicians' enthusiasm with the pill onto patients: "I suppose if people had been told well they’ll die 2 years later they’d still have said it’s worth it. It was so unthinkable and so new and so wonderful’"

    Although Dr. Healy recognizes the folly "But yesterday’s enthusiasms commonly pall in the face of today’s hazards"--he rationalizes lethal clinical practice: "Understandably, though, in the face of non-response or minimal responses, right from the start some clinicians increased the dose of individual neuroleptics a hundred-fold beyond what is now recognised as optimal, or added further neuroleptics to treatment cocktails when a particular neuroleptic had failed... Sometimes these dose escalations or additional treatments have been given on the back of an apparently worsening clinical state that may in fact have been made somewhat worse by the treatment being administered."
    have you heard anything about geodon. My son was put on this drug for intermittant explosive disorder.

    v

  4. #4
    Miles is offline Member
    Join Date
    Oct 2004
    Location
    USA.
    Posts
    330

    Default

    Omega2k:

    Geodon is an antipsychotic. Here is some info on what it is doing to the elderly. And if it is this horrific for them, think what it might be doing to your son. Please be careful and good luck!

    Regards,
    Miles

    ++++++++++++++++++++++++

    FDA Issues Warning on Drug Use by Elderly
    AP Online; 4/11/2005

    Dateline: WASHINGTON
    Elderly patients with dementia were significantly more likely to die prematurely if taking certain anti-psychotic drugs, the government said in an advisory Monday to health care workers and patients.

    The Food and Drug Administration is asking manufacturers of atypical anti-psychotic drugs to add to their labeling a boxed warning noting the risks and that the drugs were not approved to treat symptoms of dementia in the elderly.

    Elderly patients taking the drugs for dementia-related symptoms should consult with their doctors, the FDA said.

    The drugs were approved for treating schizophrenia and mania, and include such brands as Abilify, Zyprexa, Seroquel, Risperdal, Clozaril and Geodon. Symbyax, which is approved for the treatment of depression associated with bipolar disorder, is also included in the advisory.

    An analysis of 17 studies covering four drugs showed the rate of death for the elderly patients taking them was about 1.6 to 1.7 times the rate of death for placebo users. The causes of death varied, but most seemed to be either heart-related or from infection.

    The FDA doesn't have data to indicate how many elderly patients take this class of drugs, but agency officials believe that such prescriptions are common.

  5. #5
    Miles is offline Member
    Join Date
    Oct 2004
    Location
    USA.
    Posts
    330

    Default

    Omega2k:

    More on Geodon.

    +++++++++++++++

    Defective Drugs: Geodon (Ziprasidone): suicide
    Geodon (ziprasidone) has been linked to hyperglycemia, diabetes and other blood sugar side effects. Part of the new class of atypical antipsychotic drugs, Geodon is used to treat patients with schizophrenia and bipolar disorder.

    In August 2004, the Food and Drug Administration (FDA) and pharmaceutical giant Pfizer Inc. warned doctors that the company's antipsychotic drug Geodon has been linked to extremely high blood sugar and diabetes.

    Pfizer's letter to doctors followed a September 2003 FDA request that manufacturers of the six most widely used antipsychotic drugs revise labels to reflect additional risks. The remaining drugs affected by the FDA request include Eli Lilly's Zyprexa, Bristol-Myers Squibb's Abilify, Novartis' Clozaril, Janssen's Risperdal and AstraZeneca's Seroquel.

    The FDA asked Pfizer to add a new warning to the popular schizophrenia drug Geodon, which warns patients that Geodon can cause hyperglycemia, diabetes and other blood sugar disorders since Hyperglycemia related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. In a recent study, atypical antipychotics similar to Geodon were found to cause diabetes 50 percent more often than older drugs.

    Geodon was approved in the United States in February of 2001 for the treatment of schizophrenia and in 2004 for acute bipolar mania. It is an atypical antipsychotic medicine similar to Risperdal, Seroquel and Zyprexa.

  6. #6
    Miles is offline Member
    Join Date
    Oct 2004
    Location
    USA.
    Posts
    330

    Default

    Omega2k:

    One more: http://www.crazymeds.org/geodon.html

    Regards,
    Miles

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22